Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma (Q62016691)
Jump to navigation
Jump to search
scientific article published on 15 February 2011
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma |
scientific article published on 15 February 2011 |
Statements
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma (English)
P Moreau
F Cavallo
X Leleu
C Hulin
G Descamps
T Facon
M Boccadoro
D Mignard
J L Harousseau
15 February 2011